Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
JCO Precision Oncology · 2026-07 · 10 (7)
DOI: 10.1200/po-26-00456 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2026-07. Verfasst von Dan S Veljovich und 21 weiteren Autor:innen. Beteiligte Einrichtung: Swedish Cancer Institute, Seattle, WA. Hauptthemen laut MEDLINE: Piperazines, Ovarian Neoplasms, Pyridines, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit nennt 51 Literaturangaben.
Abstract (Originalsprache)
PURPOSE The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of a cohort of patients with ovarian cancer (OC) with CDKN2A alterations treated with palbociclib are reported. METHODS Eligible patients had advanced OC, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with CDKN2A alterations, and no remaining standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration (SD16+). Simon two-stage design with a null DC rate of 15% versus 35% (power = 0.85; α = .10) was used. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety. RESULTS Twenty-eight patients were enrolled from February 2017 to April 2023, and all had OC with a CDKN2A alteration (loss [n = 21], mutation [n = 5], and loss and mutation [n = 2]). One patient was not evaluable for efficacy because of an excluded genomic finding. Three patients had a partial response and seven had SD16+ for DC and OR rates of 38% (90% CI, 25 to 100) and 11% (95% CI, 2 to 29), respectively. The null hypothesis of 15% DC rate was rejected ( P = .004). The median PFS was 8 weeks (95% CI, 8 to 18) and the median OS was 33 weeks (95% CI, 24 to 73). Nineteen patients (68%) had at least one treatment-related grade 3-4 adverse event (AE) or serious AE including anemia, dyspnea, fatigue, leukopenia, neutropenia, and thrombocytopenia. CONCLUSION Palbociclib met the prespecified criteria to declare a signal of activity in patients with OC and CDKN2A alterations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Swedish Cancer Institute, Seattle, WA.
- American Society of Clinical Oncology, Alexandria, VA.
- Michigan Cancer Research Consortium, Lansing, MI.
- Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC.
- University of Michigan, Ann Arbor, MI.
- Sutter Cancer Research Consortium, San Francisco, CA.
ORCID-Profile: Elizabeth Garrett-Mayer, R Wendel Naumann, Andrew Gregory, Marina Frimer, Bernard Tawfik, Ramya Thota, Apostolia M Tsimberidou, Pam K Mangat, Dominique C Hinshaw, Abigail Gregory, Gina N Grantham, Susan Halabi, Richard L Schilsky
Zitieren
APA
Veljovich, D. S., Rothe, M., Garrett-Mayer, E., Ali-Ahmad, H. M., Naumann, R. W., Siedel, J., Chan, J. K., Gregory, A., Pisick, E., Adesunloye, B., Arend, R. C., Bell, M., Frimer, M., Tawfik, B., Thota, R., Tsimberidou, A. M., Mangat, P. K., Hinshaw, D. C., Gregory, A., …, & Schilsky, R. L. (2026). Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 10(7). https://doi.org/10.1200/po-26-00456
Vancouver
Veljovich DS, Rothe M, Garrett-Mayer E, Ali-Ahmad HM, Naumann RW, Siedel J, et al. Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 2026;10(7). doi:10.1200/po-26-00456
BibTeX
@article{Veljovich2026,
author = {Veljovich, Dan S and Rothe, Michael and Garrett-Mayer, Elizabeth and Ali-Ahmad, Hussein M and Naumann, R Wendel and Siedel, Jean and Chan, John K and Gregory, Andrew and Pisick, Evan and Adesunloye, Bamidele and Arend, Rebecca C and Bell, Maria and Frimer, Marina and Tawfik, Bernard and Thota, Ramya and Tsimberidou, Apostolia M and Mangat, Pam K and Hinshaw, Dominique C and Gregory, Abigail and Grantham, Gina N and Halabi, Susan and Schilsky, Richard L},
title = {Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {7},
doi = {10.1200/po-26-00456}
}
EUVIMED